Decoquinate was developed in the 1960s. It has a broad spectrum of anticoccidial activity and can be used to prevent and treat chicken coccidiosis caused by Eimeria tenella, Eimeria giant, Eimeria acervulina and Eimeria brucei.
Decoquinate has significant anticoccidial activity, can prevent intestinal damage and improve the growth performance of the host, and also has an inhibitory effect on the liver and blood stages of Plasmodium.
The core target of Decoquinate is the mitochondrial electron transport chain (ETC) of coccidia, specifically acting on complex III (Cytochrome bc1 complex, i.e. coenzyme Q-cytochrome c reductase), blocking electron transfer and resulting in blocked energy (ATP) synthesis.
Decoquinate is rapidly metabolized and has low residuals. After 3 days of discontinuation of the drug, the residual drug concentration in each tissue is less than 1×10-6ppm. It has low toxicity, good tolerance, and a wide safety range. It is still safe to use 80 times the recommended amount.
*FAQ and Knowledge